Economic Evaluation of the Management of Pain in Osteoarthritis

摘要: Economic evaluation in osteoarthritis is still uncommon, despite the many studies performed other disease settings. Policy makers are increasingly recognising that unit purchase price of drug not as meaningful cost-effectiveness analyses take into account frequency and magnitude its benefits adverse effects. Thus, there an urgent need for agreement on methods to be used allow comparisons; critical first steps consist inclusion common end-point disease-specific generic scales, concurrent assessment costs future clinical trials. When applying results from countries, careful attention should paid taking differences practice, values preferences patients, drugs resources or saved a consequence